Occipital Neuralgia

April 25, 2026

Occipital Neuralgia in 2026: The Trigeminocervical Pathway, Migraine Overlap, and Modern Treatment

Last updated: May 2026

Overview

Occipital neuralgia (ON) is a headache disorder defined by paroxysmal sharp, shooting, stabbing, or electric pain in the back of the scalp, in the distribution of the greater occipital nerve, lesser occipital nerve, or third occipital nerve. The pain often shoots from the base of the skull upward over the back of the head, and in some patients it radiates forward toward the ear, temple, eye, or even the forehead — a referral pattern that points to one of the most important and clinically useful concepts in modern headache medicine: the trigeminocervical complex.

Occipital neuralgia is uncommon (estimated incidence around 3 per 100,000 per year), but it is disabling — and it is one of the most frequently misdiagnosed headache disorders. A 2025 systematic review and meta-analysis in Cephalalgia (Melchior et al.) summarized the available data: occipital neuralgia typically presents in the fifth decade of life and predominantly affects women (about 73% of patients). Many patients carry a long history of “migraine” or “tension headache” before the diagnosis is recognized, and many patients with chronic migraine have an important component of occipital nerve sensitization that responds to occipital-nerve-directed treatment.

The biggest occipital neuralgia and migraine-overlap updates heading into Spring 2026:

The American Headache Society’s 2025 emergency department migraine guideline update (Robblee et al., Headache, December 2025) elevated greater occipital nerve blocks (GONB) to a Level A — “must offer” recommendation for adults with acute migraine in the ED requiring parenteral therapy, alongside IV prochlorperazine. This is one of the most practice-changing headache developments in years, and it does not reclassify migraine as a neck disease — it reinforces how clinically important the occipital-trigeminal connection is.
The trigeminocervical complex (TCC) is now central to how clinicians think about head pain. It explains why a problem at the back of the head can produce pain in the forehead, eye, and face — and why occipital nerve treatments help migraine, cluster headache, and other “anterior” headache syndromes.
Central sensitization is now recognized as a major driver of chronic occipital neuralgia. Sustained pain input from a sensitized greater occipital nerve doesn’t just cause local pain — it can rewire pain processing in the upper cervical spinal cord and brainstem, producing widespread sensitivity, allodynia (pain from light touch), and overlap with migraine biology. Cutaneous allodynia is present in roughly 60% of migraine patients and is associated with increased risk of migraine chronification.
The 2026 StimO multicenter randomized trial (Journal of Clinical Medicine, March 2026) showed that occipital nerve stimulation (ONS) for refractory occipital neuralgia produced greater pain reduction and quality-of-life improvement than optimized medical management at 6 months. The predefined primary endpoint (>50% pain reduction) was not formally met, but continuous pain measures favored ONS.
A 2024 systematic review of four decades of ONS evidence (Kollenburg et al., Current Pain and Headache Reports) reported response rates of 63–100% in occipital neuralgia, 35.7–100% in cluster headache, and 17–100% in chronic migraine, with 41.6–88% of patients remaining responders at ≥18 months. The most common adverse events were lead migration/fracture (13%) and local pain (7.3%).
Treatment is staged, beginning with a careful diagnostic occipital nerve block, then medical management, then advanced procedures (pulsed radiofrequency, botulinum toxin, occipital nerve stimulation) when needed. Surgical decompression remains a controversial last-resort option in carefully selected patients.

Understanding Occipital Neuralgia

The Anatomy

There are three occipital nerves, each supplying a different region of the back of the head:

Greater occipital nerve (GON) — by far the most commonly involved. The GON is the medial branch of the dorsal ramus of the C2 spinal nerve. It travels through the deep neck muscles, pierces a tendinous opening near the trapezius and semispinalis capitis, and fans out across the back of the scalp, sometimes reaching forward as far as the forehead.
Lesser occipital nerve (LON) — arises from the cervical plexus (C2/C3) and supplies the area behind the ear and the lateral posterior scalp.
Third occipital nerve (TON) — arises from C3 and supplies a smaller area of the upper neck and lower occipital scalp. It is often involved when pain originates from the C2–C3 facet joint.

Compression, entrapment, or chronic irritation of any of these nerves can cause occipital neuralgia. About 90% of cases involve the GON; about 10% involve the LON. The third occipital nerve is a less common but important contributor when upper cervical facet joint pathology is present.

The Trigeminocervical Complex — Why Back-of-Head Pain Can Feel Like a Migraine

This is the single most important concept to understand about occipital neuralgia, and it is what links occipital neuralgia to migraine.

The trigeminal nerve, which carries sensation from the face and the dura (the lining around the brain), and the upper cervical nerves (C1, C2, C3), which carry sensation from the back of the head and upper neck, share the same second-order pain neurons in the upper spinal cord. This shared zone — the lower trigeminal nucleus (the trigeminal nucleus caudalis) extending down into the C1–C3 dorsal horn — is called the trigeminocervical complex (TCC).

Several clinically important consequences flow from this anatomy:

Pain from the back of the head can refer to the front of the head, the eye, or the face. The brain cannot always tell whether incoming pain signals originated in the C2 territory (back of head) or the V1 territory (forehead/eye), because they are processed by the same neurons. This explains why a patient with occipital neuralgia may feel sharp pains shooting forward into the eye or temple, and why occipital tenderness is a common finding in migraine.
Stimulating the occipital nerve increases the activity of trigeminal pain neurons in the brainstem and upper cervical cord. Landmark studies by Bartsch and Goadsby (Brain, 2002–2003) showed this electrophysiologically — stimulation of the GON sensitizes neurons that also receive input from the dura (the migraine-relevant pain-sensitive structure inside the skull).
Treatments aimed at the occipital nerve can quiet the entire trigeminocervical system. This is why a greater occipital nerve block can relieve migraine, cluster headache, hemicrania continua, and even certain orofacial pain syndromes — not just the local occipital pain itself. The 2025 AHS emergency-department migraine guideline, which recommends GONB as a “must offer” Level A treatment for acute migraine, is built directly on this biology.

In short: the back of the head and the front of the head are connected at the level of the spinal cord and brainstem, and treating one can affect the other.

Central Sensitization in Occipital Neuralgia

When the greater occipital nerve is chronically irritated, it sends a sustained barrage of pain signals into the upper cervical spinal cord and brainstem. Over time, this chronic noxious input causes the second-order neurons in the trigeminocervical complex to become sensitized — they fire more easily, respond to lower-threshold stimuli, and recruit a wider zone of pain.

Clinically, central sensitization in occipital neuralgia produces several recognizable features:

Allodynia — pain from normally non-painful stimuli (brushing the hair, lying on a pillow, wearing a hat, glasses, earrings, or a hair tie)
Hyperalgesia — exaggerated pain from stimuli that should produce only mild discomfort
Spread of pain beyond the strict territory of the occipital nerve, sometimes to the face, temple, or even ipsilateral side of the body
Persistence of pain even after the original trigger (whiplash, muscle strain, prolonged neck posture) has resolved
Overlap with migraine — increased frequency and severity of migraine attacks in patients with chronic occipital nerve sensitization, and vice versa
Cutaneous allodynia — present in approximately 60% of migraine patients and associated with increased risk of migraine chronification

Central sensitization helps explain why chronic occipital neuralgia is harder to treat than acute occipital neuralgia, and why simply blocking the peripheral nerve sometimes provides only partial or temporary relief. The disease is no longer a peripheral nerve problem alone — it has become a central nervous system problem as well.

The Migraine Connection

The relationship between occipital neuralgia and migraine is bidirectional and biologically real:

Patients with migraine often have occipital tenderness and increased sensitivity of the greater occipital nerve, even between attacks. This is one reason the International Classification of Headache Disorders does not include “occipital migraine” as a separate entity — headache location alone does not define migraine, and many “occipital migraines” are actually migraines with prominent TCC involvement.
Migraine produces neck pain across all migraine phases — prodrome, headache, postdrome, and between attacks — reflecting trigeminovascular activation and cervical-trigeminal convergence at the TCC.
Greater occipital nerve blocks have well-established efficacy in migraine and cluster headache, in part by reducing afferent input into the trigeminocervical complex. The AHS 2025 ED guideline now requires that GONB be offered as a first-line option in acute ED migraine treatment.
Patients with chronic occipital neuralgia frequently have superimposed migraine features (photophobia, nausea, throbbing quality), reflecting shared central pathways.
Differentiating “occipital neuralgia” from “migraine with prominent occipital pain” is one of the most common diagnostic dilemmas in headache medicine — and is often best resolved by a careful, anesthetic-only diagnostic occipital nerve block.

Symptoms of Occipital Neuralgia

The classic features of occipital neuralgia include:

Sharp, shooting, electric, or stabbing pain in the back of the head — often described as “lightning” or “ice pick” pain
Paroxysmal episodes lasting seconds to minutes, sometimes superimposed on a duller continuous ache
Pain in a specific nerve distribution — typically beginning at the base of the skull and shooting upward over one side of the head, sometimes radiating forward toward the eye or temple
Tenderness over the greater occipital nerve at the base of the skull (about one inch lateral to the midline at the level of the superior nuchal line). Pressing this point often reproduces the patient’s typical pain.
Trigger maneuvers — pain provoked by hair brushing, pillow contact, certain neck positions, or palpation of the occipital region
Allodynia and scalp hypersensitivity in chronic cases
Sometimes referred pain to the eye, temple, or face, reflecting trigeminocervical convergence
Pain typically unilateral, but bilateral in about 15% of cases

How Occipital Neuralgia Differs from Migraine and Cervicogenic Headache

Feature	Occipital Neuralgia	Migraine	Cervicogenic Headache
Pain quality	Sharp, shooting, electric, stabbing	Throbbing, pulsating, deep	Dull, aching, pressure-like
Duration of episodes	Seconds to minutes (often paroxysmal)	4–72 hours	Hours to days
Distribution	Strictly occipital nerve territory, may refer forward	Often hemicranial, frontotemporal	Neck and occipital, often spreading forward
Trigger to palpation	Tenderness over GON reproduces pain	Generalized scalp allodynia in attacks	Reproduced by neck movement or posture
Associated features	Sometimes mild light/sound sensitivity	Photophobia, phonophobia, nausea, aura	Reduced cervical range of motion
Diagnostic block response	Anesthetic GON block briefly abolishes pain	Variable, often partial	Cervical zygapophyseal block helps

In practice, these conditions overlap. A single patient may have occipital neuralgia and chronic migraine and cervicogenic features — and may need a treatment plan that addresses all three.

How Occipital Neuralgia Is Diagnosed

There is no blood test, scan, or imaging study that proves a diagnosis of occipital neuralgia. The diagnosis is clinical, based on the pattern of symptoms, the exam, and the response to a diagnostic occipital nerve block.

ICHD-3 Diagnostic Criteria (Simplified)

The International Classification of Headache Disorders, 3rd edition, defines occipital neuralgia by:

Unilateral or bilateral pain in the distribution of the greater, lesser, or third occipital nerve
Pain has at least two of three characteristics: (a) recurring in paroxysms lasting seconds to minutes, (b) severe in intensity, (c) shooting, stabbing, or sharp in quality
Pain is associated with both: (a) dysesthesia and/or allodynia in the affected nerve territory, and (b) tenderness over the affected nerve branches or trigger points at the emergence of the GON
Pain is temporarily relieved by a local anesthetic block of the affected nerve
Not better accounted for by another diagnosis

The fourth criterion — temporary relief by a diagnostic local anesthetic block — is essential. This is what separates occipital neuralgia from a migraine that happens to feel occipital.

The Workup at Los Altos Neurology

A thorough evaluation typically includes:

Detailed history, with attention to onset (whiplash, trauma, prolonged neck posture, recent surgery), pain quality, distribution, triggers, and associated migraine-like features
Neurological examination, focused on cranial nerves, motor and sensory function, and signs that would suggest a more serious underlying problem
Physical exam of the occipital region — palpation over the greater and lesser occipital nerves at the back of the skull, checking for the trigger point that reproduces the patient’s typical pain
Range-of-motion and palpation of the cervical spine, including specific assessment of the suboccipital muscles, upper trapezius, levator scapulae, splenius capitis, and sternocleidomastoid, which frequently harbor trigger points that contribute to pain
MRI of the brain and cervical spine when there are red flags (severe sudden onset, neurological deficits, age over 50 with new headache, history of cancer, immunosuppression, or features suggesting a structural lesion)
Diagnostic greater occipital nerve block with local anesthetic only — if it abolishes the pain for the duration of the anesthetic effect, the diagnosis is supported. A combined diagnostic-and-therapeutic block with anesthetic plus a steroid is often the next step.

Imaging Considerations

Most patients with classic occipital neuralgia have normal imaging. MRI is typically used to rule out alternative causes — cervical disc disease, Chiari malformation, occipital lesions, vertebral artery dissection, or upper cervical pathology — rather than to confirm the diagnosis. MR neurography of the greater occipital nerve has been studied as a potential diagnostic tool, with some research groups reporting good correlation with surgical findings, but the technique requires expertise, is not widely available, and its sensitivity and specificity for occipital nerve entrapment are still being defined.

Treatment of Occipital Neuralgia in 2026

Treatment is staged, escalating from conservative to interventional based on response. Because central sensitization plays a major role in chronic cases, treatment often needs to address both the peripheral nerve (where the pain starts) and the central pain pathway (where the pain is being amplified) — and any coexisting migraine alongside.

Step 1 — Conservative and Pharmacologic Management

Heat, gentle stretching, posture correction, and cervical physical therapy. Many cases of occipital neuralgia have a contributing component of upper cervical muscle tension or dysfunction, and good neck care helps both. Physical therapy that specifically targets the suboccipital muscles, trapezius, levator scapulae, splenius capitis, and sternocleidomastoid — through manual therapy, dry needling, deep cervical flexor strengthening, and scapular stabilization — can substantially reduce pain in patients with a strong myofascial component.
NSAIDs for symptom control during flares.
Tricyclic antidepressants (amitriptyline, nortriptyline) — often first-line for chronic neuropathic head pain, with the added benefit of treating coexisting migraine.
Anticonvulsants (gabapentin, pregabalin, topiramate, carbamazepine, oxcarbazepine) — useful for the neuropathic, shooting quality of the pain, and topiramate has additional migraine-prevention benefits.
SNRIs (duloxetine, venlafaxine) — useful when chronic pain, mood, sleep disturbance, or widespread sensitization is present.
Muscle relaxants when cervical muscle spasm is a clear contributor.
Avoidance of opioids and butalbital-containing combinations, which drive both central sensitization and medication-overuse headache. Daily acute-pain medication use is one of the most common reasons treatment fails.

Step 2 — Greater Occipital Nerve Block (Diagnostic and Therapeutic)

The greater occipital nerve block is the cornerstone of occipital neuralgia management. A small volume of local anesthetic (typically lidocaine or bupivacaine), often combined with a corticosteroid, is injected near the GON at the back of the skull.

Diagnostic value: prompt pain relief during the anesthetic phase strongly supports the diagnosis.
Therapeutic value: the steroid component can provide weeks to months of relief in many patients.
Migraine-modulating effect: by reducing input into the trigeminocervical complex, GON blocks can also reduce migraine and cluster-headache frequency. The 2025 AHS ED guideline now recommends GONB as a Level A “must offer” treatment for acute migraine in the emergency department — making it one of only two treatments at that recommendation level (alongside IV prochlorperazine), while specifically recommending against IV hydromorphone.
Ultrasound guidance improves precision over landmark-based injection in many practices, particularly when anatomy is variable, prior procedures have altered local tissue, or a more proximal block (near the C2 emergence) is desired. Mayo Clinic and others have studied proximal C2-level ultrasound-guided GONB as a more anatomically targeted alternative when distal landmark blocks have provided incomplete relief.

GON blocks are typically repeated as needed when symptoms return. A patient who responds reliably to repeated blocks is a good candidate for more durable interventions.

Step 3 — Treating Coexisting Migraine

This is often the missing step. If a patient has migraine plus occipital pain, treating the occipital nerve alone is rarely enough.

Modern migraine treatment has expanded substantially in the CGRP era. Options include:

Acute treatment: triptans (sumatriptan, rizatriptan, etc.), gepants (rimegepant, ubrogepant, zavegepant), ditans (lasmiditan), NSAIDs, antiemetics, and — in the ED setting — IV prochlorperazine and GONB
Preventive monoclonal antibodies targeting CGRP: erenumab, fremanezumab, galcanezumab, eptinezumab
Preventive gepants: atogepant, rimegepant
OnabotulinumtoxinA (Botox) for chronic migraine — well-established benefit, partly mediated by reduced afferent input into the trigeminocervical complex
Traditional preventives: topiramate, beta-blockers, candesartan, venlafaxine, nortriptyline, depending on the patient
Lifestyle and trigger management: sleep optimization, hydration, regular meals, stress management, and reducing medication overuse

A patient with migraine plus occipital nerve sensitization will often do best when both are treated in parallel. Untreated migraine drives central sensitization and worsens occipital pain, and untreated occipital nerve irritation feeds back into the migraine circuit.

Step 4 — Botulinum Toxin

OnabotulinumtoxinA injection into the occipital and pericranial muscles is approved for chronic migraine and is sometimes used for occipital neuralgia, especially when there is significant overlap with chronic migraine or substantial muscle component.

The evidence picture is important to communicate clearly: a 2025 review summarized by the International Association for the Study of Pain found botulinum toxin efficacy specifically for occipital neuralgia to be undetermined, citing the lack of high-quality blinded studies and calling for larger controlled trials. Botox is therefore very reasonable when the patient has chronic migraine with prominent occipital features, but it should not be oversold as a proven stand-alone treatment for pure occipital neuralgia.

Step 5 — Pulsed Radiofrequency and Radiofrequency Ablation

For refractory cases, pain specialists may consider pulsed radiofrequency (PRF) — brief, high-intensity electromagnetic field pulses that modulate nerve function without producing the heat-induced nerve destruction of conventional radiofrequency. A 2024 systematic review (22 studies, 608 patients) found PRF reduced headache intensity in occipital neuralgia and several other primary headache disorders, with a generally favorable safety profile, although study quality was variable and randomized data remain limited.

Conventional thermal radiofrequency ablation (RFA) creates a more durable lesion and is more commonly considered when a specific joint-mediated or nerve-mediated pain generator is confirmed. Third occipital nerve RFA is a particularly useful option when C2–C3 facet joint pain is strongly suspected and diagnostic third-occipital-nerve or medial branch blocks have produced reproducible relief. This is a well-established technique in interventional pain medicine for cervicogenic headache with a TON component.

Risks of any radiofrequency procedure may include numbness, neuritis, dysesthesia, temporary worsening, or incomplete relief, so careful patient selection is essential.

Step 6 — Occipital Nerve Stimulation (ONS)

Occipital nerve stimulation involves implanting a thin electrode under the skin near the greater occipital nerves, connected to a small battery (similar to a pacemaker), which delivers gentle electrical pulses that modulate pain processing in the trigeminocervical complex.

A 2024 systematic review of four decades of ONS evidence (Kollenburg et al., Current Pain and Headache Reports) reported response rates of 63–100% in occipital neuralgia, with 41.6–88% of patients remaining responders at ≥18 months. The most common adverse events were lead migration or fracture (about 13%) and local pain (about 7%).

The 2026 StimO multicenter randomized controlled trial (Journal of Clinical Medicine, March 2026) compared ONS with optimized medical management (OMM) in patients with refractory occipital neuralgia:

The predefined primary endpoint (>50% pain reduction at 6 months) was not formally met, although continuous measures of pain reduction favored ONS.
ONS produced greater reduction in maximum and average pain intensity at 3 and 6 months.
ONS patients had better quality of life and reduced medication burden.

The bottom line from the current ONS evidence is that it is a reasonable option for carefully selected refractory patients who have failed conservative care, medications, nerve blocks, and less invasive procedures, but the trial evidence does not yet demonstrate clear superiority on strict primary endpoints.

Step 7 — Surgical Decompression

For patients with clear-cut occipital nerve entrapment — typically at the trapezial tunnel where the GON pierces the trapezius aponeurosis — surgical decompression by a peripheral nerve specialist can provide durable relief. This is most often considered when:

The diagnosis is well-established by repeated nerve blocks
Imaging or examination supports a specific entrapment point
Multiple non-surgical treatments have failed
The patient understands realistic expectations and surgical risks

Surgical decompression remains controversial in cases where chronic migraine and occipital neuralgia overlap. The most recent surgical literature emphasizes the importance of accurate anatomical assessment and complete decompression — incomplete decompression is a common reason for surgical failure.

Emerging Research and 2026 Trends

Greater Occipital Nerve Block Has Become a Pillar of Migraine Care

The 2025 AHS emergency department migraine guideline update is genuinely practice-changing. By elevating GONB to Level A — “must offer” alongside IV prochlorperazine, and explicitly recommending against IV hydromorphone (Level A “must not offer”) — the guideline reframes nerve blocks as core, evidence-based migraine treatment rather than a niche option. This does not turn migraine into a neck disease. Instead, it formalizes the clinical reality that the greater occipital nerve is a highly useful access point into the trigeminocervical pain network.

Ultrasound-Guided and Proximal Techniques Are Refining Precision

There is growing interest in whether proximal ultrasound-guided GON blocks near the C2 emergence are more anatomically precise than traditional landmark-guided distal blocks in selected patients — particularly when symptoms suggest deeper cervical involvement, when standard blocks provide incomplete relief, or when prior surgery has altered the local anatomy.

Platelet-Rich Plasma Remains Investigational

A 2024 pilot randomized, double-blind, placebo-controlled trial (Stone et al., Frontiers in Neurology) studied PRP injections for post-traumatic greater occipital neuralgia after concussion in 32 adults. PRP was feasible and safe, but did not show a clear advantage over saline or steroid/anesthetic injection at the studied endpoints. Larger trials are needed before PRP can be considered standard treatment for occipital neuralgia.

Central Sensitization Is Becoming a Treatment Target

More headache specialists are explicitly assessing allodynia, medication overuse, sleep, mood, and pain amplification rather than treating only the most tender nerve. Once the trigeminocervical pathway and migraine network become sensitized, treatment usually needs to be broader and more sustained — addressing both the peripheral driver and the central network. A 2025 narrative review on the cervicotrigeminal complex (Frontiers in Pain Research) explicitly recommended a stepwise, mechanism-based approach to refractory head and neck pain, treating the TCC as a “targetable hub” rather than chasing individual symptoms.

Conditions That Can Mimic or Coexist With Occipital Neuralgia

Cervicogenic headache — pain originating from upper cervical joints (C1–C2, C2–C3 zygapophyseal joints), often producing pain that radiates from the neck forward. Relieved by cervical medial branch blocks, third occipital nerve blocks, or facet-directed treatment.
Migraine with prominent occipital features — true migraine biology producing pain that includes the back of the head. The pain is throbbing rather than shooting and lasts hours rather than seconds.
Cluster headache and other trigeminal autonomic cephalalgias — strictly unilateral, severe, with autonomic features (tearing, nasal congestion, eyelid drooping); peri-orbital but can extend posteriorly.
Cervical disc disease, facet arthropathy, or myofascial pain — neck-dominant pain that may radiate up through trigger points in the suboccipital, trapezius, levator scapulae, splenius capitis, and sternocleidomastoid muscles.
Post-concussion / post-traumatic headache — often a mixed picture of migraine, occipital neuralgia, cervicogenic features, vestibular symptoms, sleep disruption, and central sensitization.
C2 radiculopathy — distinct from occipital neuralgia, but can produce overlapping symptoms.
Chiari malformation type I — cough-induced occipital headache; identified on MRI.
Vertebral artery dissection — sudden severe occipital/neck pain; a medical emergency.
Posterior fossa lesions (rare) — tumors, vascular malformations; identified on MRI.
Greater occipital nerve neuroma following surgery or trauma.
Giant cell arteritis — in patients over 50, new scalp tenderness, jaw claudication with chewing, vision changes, fever, weight loss, or elevated inflammatory markers should prompt urgent evaluation. Untreated giant cell arteritis can cause permanent vision loss.
Trigeminal neuralgia or trigeminal neuropathy — facial, jaw, or eye pain rather than occipital, although TCC convergence can blur the boundaries.

The reason imaging and labs are part of a thorough evaluation is to rule out the dangerous mimics — not to confirm occipital neuralgia, which remains a clinical diagnosis.

A Practical Framework for Patients — Four Questions

When evaluating any patient with chronic posterior head pain, four questions should guide the assessment:

Is this true occipital neuralgia? Sharp, shooting, paroxysmal pain in the back of the head, with reproducible tenderness over the greater occipital nerve, relieved temporarily by an anesthetic block. If the pain is throbbing and lasts hours, migraine is more likely.
Is migraine also present? Coexisting migraine is common and often under-treated. Photophobia, phonophobia, nausea, family history, and trigger sensitivity all point toward a migraine component that needs its own treatment plan — including modern CGRP-targeted preventives when appropriate.
Is the cervical spine or myofascial system contributing? Upper cervical facet joint pathology, prior whiplash, prolonged neck flexion, or active trigger points in the suboccipital, trapezius, levator scapulae, splenius capitis, and sternocleidomastoid muscles can drive or amplify the pain.
Has the pain system become centrally sensitized? Allodynia, scalp hypersensitivity, spread of pain beyond the original territory, pain with light touch, and disproportionate disability all suggest that the trigeminocervical complex and broader pain network are now amplifying input — and that treatment will need to be broader than a single injection.

The best outcomes usually come from a treatment plan that addresses all four contributors simultaneously — peripheral nerve, cervical/myofascial, migraine biology, and central sensitization — rather than chasing one in isolation.

When to Seek Urgent Medical Care

Patients with posterior head pain should seek urgent evaluation for any of the following:

Sudden “worst headache of life” or thunderclap onset
New neurological symptoms — weakness, numbness, speech difficulty, confusion, double vision, loss of balance
New or changed headache after major head/neck trauma
Fever, stiff neck, rash, or immune suppression
New headache after age 50, particularly with scalp tenderness, jaw pain when chewing, or vision changes (concern for giant cell arteritis)
Headache in the setting of cancer history, pregnancy/postpartum state, or anticoagulation
Progressive worsening or a major change in established headache pattern
Headache associated with focal neurological deficits

Occipital neuralgia is painful but rarely dangerous. The danger is missing a different condition that is pretending to be occipital neuralgia. A careful first evaluation is the most important step.

Bottom Line

Occipital neuralgia is a real, distinct, and treatable cause of severe head pain — but it is also tightly connected to migraine and to the broader biology of central sensitization through the trigeminocervical complex. Understanding this connection has changed the way modern headache specialists approach the disorder:

The back of the head and the front of the head are connected through shared pain neurons in the upper spinal cord and brainstem.
Chronic peripheral nerve irritation can rewire central pain processing, producing widespread sensitivity, cutaneous allodynia, and overlap with migraine.
The 2025 AHS emergency department guideline elevated greater occipital nerve blocks to a Level A “must offer” treatment for acute migraine — formalizing what headache specialists have observed clinically for years.
Treating occipital neuralgia well usually means treating both the peripheral nerve and the central pain network — and treating any coexisting migraine alongside it, including with CGRP-targeted therapies when appropriate.
The treatment ladder progresses from conservative measures to nerve blocks, pulsed radiofrequency or third occipital nerve RFA, botulinum toxin (best evidence in chronic migraine, undetermined for pure occipital neuralgia), occipital nerve stimulation, and selectively surgical decompression.
The four guiding questions — true occipital neuralgia, migraine present, cervical/myofascial contribution, central sensitization — produce more accurate diagnoses and better treatment plans than chasing the most tender spot.

At Los Altos Neurology, we provide thorough headache evaluations that distinguish occipital neuralgia from migraine, cervicogenic headache, giant cell arteritis, post-traumatic headache, and other mimics; perform diagnostic-and-therapeutic greater occipital nerve blocks; and coordinate a stepwise, individualized treatment plan that may combine medical management, interventional procedures, and modern migraine therapies when appropriate. The goal is not just to suppress pain in the moment, but to calm the underlying trigeminocervical system so that it stops driving recurrent attacks.

Occipital Neuralgia

Occipital Neuralgia in 2026: The Trigeminocervical Pathway, Migraine Overlap, and Modern Treatment

Overview